TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Stratum 1:~  * Diagnosis of neurofibromatosis 1 (NF1) and plexiform neurofibromas~ * At high risk for progression, as defined by any of the following:~    * Anatomic location such that progression carries a high risk of impairment of function, pain, or disfigurement (e.g., neck/mediastinum, paraspinal nerve roots, orbit, and face)~   * Tumors that the patient, family, or caregiver believes have increased in size within the past year, but appear stable by standard clinical or radiographic measures~ * No plexiform neurofibromas that are small, cause no pain or functional impairment, or are not likely to cause pain or functional impairment over the succeeding 12 months~* Stratum 2:~  * Diagnosis of NF1 and progressive plexiform neurofibromas~    * Neurofibroma progression documented by increase in lesion size on MRI~ * Currently being enrolled on a clinical therapeutic trial at Children's Hospital of Philadelphia~PATIENT CHARACTERISTICS:~Age~* 25 and under~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* Not pregnant or nursing~* Negative pregnancy test~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Stratum 1:~  * No prior or concurrent chemotherapy~ * No concurrent enrollment on a chemotherapy clinical trial~* Stratum 2:~  * At least 4 weeks since prior chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* At least 6 weeks since prior radiotherapy (stratum 2)~Surgery~* Prior surgery for progressive plexiform neurofibroma allowed if incompletely resected and measurable disease remains (stratum 2)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- 18FDG-PET scan and MR perfusion (Type: EXPERIMENTAL): Subjects will undergo MRI for quantitative (2D and 3D) evaluation of plexiform neurofibroma size, MR perfusion scan, and fludeoxyglucose (18FDG) PET scan at the time of study entry. Subjects who are treated for plexiform neurofibroma will undergo another 18FDG PET scan after one year of study entry.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observation Versus Immediate Surgery of Low Risk Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of low grade, noninvasive urothelial carcinoma of the bladder with a new recurrence that meets the following criteria:~* total tumor burden ≤3cm in size (multiple lesions permitted)~* low grade appearance (grade 1 or grade 2)~* noninvasive appearance (Ta)~* no history of carcinoma in situ (CIS) or lesions concerning for CIS~* negative urine cytology (atypical or suspicious for low grade neoplasm are acceptable)~Exclusion Criteria:~* High grade and/or invasive and/or carcinoma in situ disease~* Concomitant upper tract urothelial carcinoma~* Any patient who is pregnant or who may have plans to become pregnant.~* Positive cytology

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observation (Type: OTHER): Patients will not undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Surgery will commence after 12 months of observation or sooner if cystoscopic evidence of disease progression or patient desire.
- Immediate Surgery (Type: OTHER): Patients will undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Repeated surgery will be offered for additional recurrences.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antibody Production in Immune Disorders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Individuals being evaluated by NIH investigators for known or suspected primary immune disorders.~Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for at least 21 days prior to receipt of each vaccine and for the duration of study participation.~EXCLUSION CRITERIA:~Documented HIV infection.~Active malignancy.~Immunosuppressive therapy, other than steroids.~Symptomatic cardiac disease or ongoing treatment for it.~Pregnant or lactating women (due to restrictions on use of vaccines).~Surgery during the two weeks prior to entry.~Serious, ongoing, or uncontrolled infections.~Platelet count less than 40,000/microL or other coagulation disorder.~Any other major illness that, in the investigator's judgment, may substantially increase the risk associated with the patient's participation in this study.~History of previous systemic reaction to the particular vaccine product being considered for administration.~For RabAvert, persons known to be sensitive to:~* Processed bovine gelatin~* Chicken protein~* Neomycin~* Chlortetrycyline~* Amphotericin B~For Prevnar, persons with know or possible latex sensitivity.~The effects of the vaccines on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for at least 21 days prior to each vaccine and for the duration of study participation. Females of child bearing age will have a pregnancy test prior to each vaccination. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform study staff and her primary care physician immediately.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pneumococcal Vaccine (Type: ACTIVE_COMPARATOR): To determine the function of T and B cells in vivo using Pneumococcal vaccine immunization in patients with known or suspected immune disorders.
- Rabies Vaccine (Type: ACTIVE_COMPARATOR): To determine the function of T and B cells in vivo using Rabies vaccine immunization in patients with known or suspected immune disorders.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenomics Information in Enhancing Post-operative Total Joint Replacement Pain Management: a Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients undergoing total knee arthroplasty Patients able to understand study intent, and agree to study participation. Patients with a history of preoperative narcotic dependence and/or, adverse reactions to narcotics, and/or have experienced ineffective pain management with narcotics.~Exclusion Criteria:~Patients with orthopaedic and medical co-morbidities that would thwart postoperative pain control such as extra-articular pathology with referred pain to the knee (spinal stenosis, neuropathy,ipsilateral hip disease), severe knee deformity, post-traumatic and inflammatory arthritis Patients with chronic pain disorders BMI \> 40 ASA class \> III GI bleed within 6 months of surgery History of drug or alcohol abuse Patients unable to receive multimodal pain remitting agents including Celecoxib and Pregabalin.~Patients with diabetes and patients who are unable to receive decadron Any patient receiving general anesthesia Patients who will need to go to an ECF upon discharge Patients who are pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Genetic Panel for Analgesics (Type: OTHER): Genetic testing for analgesics prior to surgery will be conducted. The subject will receive postoperative analgesia based on test results.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~Women who:~* request elective pregnancy termination in one of the sites participating into the study~* are prescribed mifepristone-misoprostol for this purpose~* provide informed consent to participate in the study.~Exclusion Criteria:~* Participant who is unable to understand or comply with Health Care Professional instructions or medical abortion regimen~* Participant who is unable or unwilling to provide written informed consent.

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HPV Vaccination in Special Risk Groups: 5 Year Follow-up

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Females who participated in the initial HPV vaccine immunogenicity study in 2007.~Exclusion Criteria:~* Inability to provide informed consent

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: 26 Years
- Healthy Volunteers: f

Study Arms:
- PRD patrients (Type: None): Children/adolescent females 12-26 years with a PRD such as JIA (Juvenile Idiopathic Arthritis) or SLE (Systemic Lupus Erythematosus)~Subgroups:~1. receiving immunosuppressant therapy~2. not on immunosuppressant therapy
- IBD patients (Type: None): Children/adolescent females 12-26 years diagnosed with IBD.~Subgroups:~3. receiving immunosuppressant therapy 4. not on immunosuppressant therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Haelan and Nutrition in Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Anorexia (defined as \> 30mm on a visual analog scale \[VAS\] of 0 to 100mm)~2. Weight loss (defined as weight loss \> 5% within last 6 months)~3. Normal cognition (per treating physician's opinion)~4. Written informed consent~5. Advanced solid tumor (defined as locally recurrent or metastatic disease)~6. Patient must have perceived weight loss as a problem.~7. Able to maintain oral food intake within one week prior to enrollment in this study.~Exclusion Criteria:~1. Evidence of ascites (per treating physician's opinion).~2. Receiving supplementary tube feedings or parenteral nutrition~3. Known mechanical obstruction of the alimentary tract, or intractable vomiting~4. Add or change dose of the following medication within 2 weeks prior to this trial or during this trial: megestrol, corticosteroid, mirtazapine, metoclopramide and dronabinol, with the exception of pre-medication for chemotherapy (10-20 mg Decadron intavenous (IV) once and/or Reglan 10 mg IV x1 prior to chemotherapy).~5. Allergic to soy.~6. Positive pregnancy test for female patients of child-bearing potential. (Definition of child-bearing potential: not post-menopausal for past 12 months or nor surgically sterile)~7. Female patients with child bearing potential, but refuse to practice accepted methods of contraception (acceptable forms of contraception include: continuous abstinence, Depo-Provera shot, tubal ligation, NuvaRing vaginal ring, Ortho Evra skin patch, oral contraceptive, IUD-Mirena, vasectomy, male condom, diaphragm).~8. Weight less than 80 lb.~9. Patient who could not tolerate oral intake of 2 Oz. of Haelan during the taste test.~10. Diagnosed of breast cancer.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fermented Soy Supplement (Type: OTHER): 4 oz Haelan orally twice daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Daily HemoDialysis at Low Dialysate Flow in Patients Previously Treated With Conventional Hemodialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Patients who give voluntary signed informed consent~* Patients affiliated with the French universal health care system or similar~* For women of childbearing potential: serum or urine negative pregnancy test~* Patients treated with conventional hemodialysis (3 times 4h to 5h per week at at least a dialysate flow rate of 500 ml/min) for at least 3 months and clinically stable (investigator assessment)~* Bipuncture patients (or with double lumen central venous catheter) with stable vascular access and easy to puncture~* Patients willing to be treated with daily hemodialysis at low dialysate flow during the study period (6 times 2h to 2h30 per week at a dialysate flow rate of 200 ml/min in order that the total duration of weekly dialysis is equivalent to the duration of weekly dialysis during the last 3 months of conventional hemodialysis)~Exclusion Criteria:~* Pregnant women or women who could become pregnant during the study (planned pregnancy within 3 months)~* Patients not affiliated with the French universal health care system~* Minor patients~* Patients who are protected adults according to the terms of the law (French public health laws).~* Refusal to give consent~* Patients simultaneously participating in another trial that may interfere with the study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daily hemodialysis at low dialysate flow (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Known diagnosis of type 2 diabetes mellitus (T2DM) with glycosylated hemoglobin (HbA1c) between 6.5% and 10%, inclusive.~  * Stable doses of oral antihyperglycemic agents for at least 2 months~ * Stable dose of chronic insulin therapy for at least 2 months~ * HbA1c documented within 3 months before study enrollment~* Planned first elective coronary artery bypass graft (CABG) surgery~Exclusion Criteria:~* Elevated Creatine Kinase-Myocardial Bands (CK-MB) or troponin level above the 99th percentile at screening~* Receiving incretin therapy or having received incretin therapy within the previous 2 months~* Type 1 DM or a history of ketoacidosis~* Women who are pregnant or breastfeeding~* Known end-stage Kidney disease~* Known sensitivity or intolerance to saxagliptin or dipeptidyl peptidase-4 (DPP-4) inhibitor~* Clinically apparent liver disease~* History of pancreatitis

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin (Type: ACTIVE_COMPARATOR): Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
- Placebo (Type: PLACEBO_COMPARATOR): Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive Detection of Male Infertility With FDG-PET/MRI (Spectroscopy and DWI)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~18-40 year old males referred to fertility treatment at Rigshospitalet, Denmark. 10 men with a normal sperm count and 10 men with no sperm cells in the ejaculate will be included. The patients shall be able to understand the patient information and be able to give informed consent.~Exclusion Criteria:~Severe claustrophobia Age: less than 18 or above 40 Severe obesity (\> 140 kg) Pacemaker or other electronic in-operated devices Non-MR compatible metallic devices Malignant testicular tumors suspected at clinical examination or ultrasound Infectious testicular diseases

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- PET/MRI (Type: OTHER): All participants will have a PET/MRI performed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with active ulcerative colitis~* Patients who have been receiving an oral 5-ASA formulation at a fixed regimen and at a fixed dose~* Either inpatient or outpatient~Exclusion Criteria:~* Patients who have a history of intestinal resection (other than appendiceal resection)~* Patients who have a complication of malignant tumor~* Female patients who are pregnant, lactating, or possibly pregnant, or who wish to become pregnant during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of squamous cell cancer of the head and neck - unresectable or metastatic. Must have measurable disease by RECIST.~* Karnofsky performance status greater than or equal to 60%~* Up to one prior systemic chemotherapy, immunotherapy allowed in the advanced or metastatic setting. This does not include prior chemotherapy, immunotherapy used with radiotherapy (ie concurrent with radiation therapy or as and induction regimen pror to definitive radiation therapy).~* At least 4 weeks from prior radiation or chemotherapy, must have recovered from all acute effects of treatment.~* Adequate organ and marrow function~* Negative pregnancy test. Agree to use birth control during and for 3 months after last dose of study drug.~* At least 18 years of age.~* Sign an informed consent and HIPAA consent.~* Must be able to take and absorb enteral medication.~Exclusion Criteria:~* Serious concomitant systemic disorder that would compromise safety or ability to complete study.~* Prior treatment with gemcitabine or pemetrexed within the previous year, unless used concurrently with radiation therapy.~* Pregnancy or breastfeeding.~* Symptomatic or uncontrolled brain mets. If treated, must be off steroids for at least 2 weeks.~* Inability or unwilling to take folic acid, vitamin B12, or dexamethasone.~* Treatment within last 30 days with a drug that has not received regulatory approval for any indication.~* Inability to interrupt and NSAID or salicylate with a long half-life (piroxicam or nabumetone) for a 5 day period.~* Presence of clinically relevant third space fluid that cannot be controlled by drainage or other procedure prior to study entry.~* Active, concurrent, invasive malignancy requiring ongoing treatment.~* Corticosteroids impermissible unless for adrenal failure, septic shock or as temporizing measure for symptomatic pain, breathing, or rash.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed and gemcitabine (Type: EXPERIMENTAL): pemetrexed 500mg/m2 and gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy